Global Bio/Pharma CapEx Soars, Would Rather ‘Make Than Buy,’ Says PharmSource

Leader in contract bio/pharma industry intelligence says preference for in-house manufacture continues

Fairfax, VA (September 23, 2016) – Global and generic bio/pharmaceutical companies will continue to prefer in-house manufacturing to outsourcing for the most strategic elements of their businesses, according to PharmSource Information Services, Inc.

This forecast is well authenticated in a report published by the industry’s preeminent expert, PharmSource Information Services, Inc. Having spent over $150 billion for new plant and equipment in the past 5 years, it’s clear that global bio/pharma companies would rather “make than buy.”

The new report, Bio/Pharma CapEx Trends 2016, states that captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry.

In developing the report, PharmSource’s experts researched financial data for nearly 520 publicly traded companies, along with a dataset of 140 announced manufacturing and R&D infrastructure investment projects. The data captures the bulk of industry capital spending and paints an illustrative picture of how companies are investing in facilities and equipment.

This PharmSource report is an update to the previous analysis, Bio/Pharma CapEx Trends: Sponsor Spending on In-House Capacity Trounces Outsourcing, published in 2014. It is considered required reading for CMO executives and strategic decision-makers who follow the global CMO industry, including dose and API manufacturers.

PharmSource is the recognized unbiased authority of knowledge about the global bio/pharmaceutical contract services industry. The company’s proprietary publications, database platforms, research tools and analyses inform buyers and sellers of bio/pharma contract services about industry trends, activities and partnership opportunities.

Since 1996, bio/pharmaceutical companies, CMOs, CDMOs and CROs worldwide have looked to PharmSource for expert information delivered with timeliness and integrity. To learn why 80% of the largest bio/pharmaceutical companies, and 80% of the top global CMOs, rely on PharmSource, visit